JP2010511382A - 癌関連タンパク質キナーゼ - Google Patents

癌関連タンパク質キナーゼ Download PDF

Info

Publication number
JP2010511382A
JP2010511382A JP2009539218A JP2009539218A JP2010511382A JP 2010511382 A JP2010511382 A JP 2010511382A JP 2009539218 A JP2009539218 A JP 2009539218A JP 2009539218 A JP2009539218 A JP 2009539218A JP 2010511382 A JP2010511382 A JP 2010511382A
Authority
JP
Japan
Prior art keywords
ack1
epha2
tyk2
lmtk2
ron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009539218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511382A5 (enExample
Inventor
アクセル ウーリッヒ、
ジェンス リューエ、
ステファン ハート、
シルビア ストレイト、
チー ホン ウォン、
ブーン ティン チュア、
ハン キアット ホー、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of JP2010511382A publication Critical patent/JP2010511382A/ja
Publication of JP2010511382A5 publication Critical patent/JP2010511382A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G01N33/57557—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G01N33/57525—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2009539218A 2006-12-01 2007-12-03 癌関連タンパク質キナーゼ Pending JP2010511382A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86817306P 2006-12-01 2006-12-01
PCT/SG2007/000412 WO2008066498A1 (en) 2006-12-01 2007-12-03 Cancer-related protein kinases

Publications (2)

Publication Number Publication Date
JP2010511382A true JP2010511382A (ja) 2010-04-15
JP2010511382A5 JP2010511382A5 (enExample) 2011-01-27

Family

ID=39468190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539218A Pending JP2010511382A (ja) 2006-12-01 2007-12-03 癌関連タンパク質キナーゼ

Country Status (5)

Country Link
US (1) US20110008347A1 (enExample)
EP (1) EP2094850B1 (enExample)
JP (1) JP2010511382A (enExample)
SG (1) SG177225A1 (enExample)
WO (1) WO2008066498A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500638A (ja) * 2011-11-30 2015-01-08 ジェネンテック， インコーポレイテッド 癌におけるｅｒｂｂ３変異
JP2017531433A (ja) * 2014-10-09 2017-10-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 上皮細胞増殖因子受容体キナーゼドメインにおける変異

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
JP2010515921A (ja) * 2007-01-11 2010-05-13 ジェネンテック， インコーポレイテッド 腫瘍と関連している遺伝的変異
KR101561403B1 (ko) 2007-08-30 2015-10-16 다이이찌 산쿄 가부시키가이샤 항ｅｐｈａ２ 항체
JP2011509079A (ja) * 2007-12-24 2011-03-24 オックスフォード ビオトヘラペウトイクス エルティーディー． エフリンａ型受容体１０タンパク質
EP2252373B1 (en) * 2008-02-05 2012-06-13 Urifer Ltd Novel fer -like protein, pharmaceutical compositions containing it and method for its use
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP2165710A1 (en) * 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
EP2169071A1 (en) * 2008-09-29 2010-03-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rodent cancer model for human FGFR4 Arg388 polymorphism
PE20120021A1 (es) 2008-10-10 2012-02-10 Amgen Inc Mutantes fgf21
JP5439494B2 (ja) * 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
KR102672712B1 (ko) 2008-11-12 2024-06-07 인리젠 분리된 신장 세포 및 이의 용도
JP5979877B2 (ja) * 2009-02-12 2016-08-31 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト癌における変異ｒｏｓ発現
AU2010246108B2 (en) * 2009-05-05 2014-10-23 Amgen Inc. FGF21 mutants and uses thereof
MX2011011815A (es) 2009-05-05 2012-01-27 Amgen Inc Mutantes fgf21 y usos de los mismos.
EP2336171A1 (en) * 2009-12-11 2011-06-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel targets for the treatment of proliferative diseases
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
TWI542690B (zh) 2010-05-12 2016-07-21 再生醫學Ｔｘ有限責任公司 生物活性腎細胞
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012068073A2 (en) 2010-11-15 2012-05-24 University Of Florida Research Foundation, Inc. Therapeutic and diagnostic applications targeting tnk-1
WO2012075158A1 (en) 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
US10293035B2 (en) 2014-03-28 2019-05-21 University Of Washington Through Its Center For Commercialization Breast and ovarian cancer vaccines
US11946934B2 (en) 2014-09-03 2024-04-02 Wellmarker Bio Co., Ltd. Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof
CA2987281A1 (en) * 2015-05-29 2016-12-08 Ignyta, Inc. Compositions and methods for treating patients with rtk mutant cells
WO2017070708A1 (en) 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
SG11201803098VA (en) 2015-10-30 2018-05-30 Nbe Therapeutics Ag Anti-ror1 antibodies
JP7000660B2 (ja) 2016-01-20 2022-02-04 ザ スクリプス リサーチ インスティテュート Ｒｏｒ１抗体組成物及び関連の方法
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
CN106480205A (zh) * 2016-11-11 2017-03-08 北京吉因加科技有限公司 用于同时检测多种突变类型的序列组合和探针
BR112020000793A2 (pt) 2017-07-19 2020-07-14 Ignyta, Inc. composições farmacêuticas e formas de dosagem
CA3071212C (en) 2017-08-07 2023-12-12 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
US12077599B2 (en) * 2017-11-29 2024-09-03 Seoul National University R&Db Foundation, National Cancer Center Anti-ROS1 antibody and use thereof
WO2019133752A1 (en) * 2017-12-28 2019-07-04 Development Center For Biotechnology A method for predicting drug efficacy
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
WO2020179844A1 (ja) * 2019-03-04 2020-09-10 公益財団法人東京都医学総合研究所 Ｔｒｋ断片をコードする核酸構築物、及びその利用
CN110031626A (zh) * 2019-04-02 2019-07-19 浙江理工大学 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
EP4085055A1 (en) 2019-12-30 2022-11-09 Tyra Biosciences, Inc. Aminopyrimidine compounds
MX2023007793A (es) 2020-12-30 2023-09-22 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas.
EP4297873A1 (en) 2021-02-26 2024-01-03 Tyra Biosciences, Inc. Aminopyrimidine compounds and methods of their use
EP4547670A1 (en) 2022-06-29 2025-05-07 Tyra Biosciences, Inc. Polymorphic compounds and uses thereof
US20250368666A1 (en) 2022-06-29 2025-12-04 Tyra Biosciences, Inc. Indazole compounds
WO2024138112A1 (en) 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds
TW202535368A (zh) 2023-12-15 2025-09-16 美商泰拉生物科學公司 吲唑化合物
WO2025222097A1 (en) 2024-04-19 2025-10-23 Tyra Biosciences, Inc. Indazole-based protac degraders and their anticancer activity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343940A (en) * 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
DE3069468D1 (en) * 1979-12-19 1984-11-22 Nat Res Dev Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3611194A1 (de) * 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3920029C2 (de) * 1988-06-30 1999-05-20 Clariant Finance Bvi Ltd Farbstoffe zum Färben von Kunststoffen
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SE517975C2 (sv) 2000-05-30 2002-08-13 Power Ab C Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion
JP2004533206A (ja) * 2000-10-11 2004-11-04 アバロン　ファーマシューティカルズ 化学療法のための標的としてのガン関連遺伝子
US20050191618A1 (en) 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
US20030157082A1 (en) * 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
JP2006174701A (ja) * 2003-02-24 2006-07-06 Research Association For Biotechnology 新規タンパク質およびそれをコードするｄｎａ
JP2005198640A (ja) * 2003-11-25 2005-07-28 Biomarker Science:Kk 遺伝子発現方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012059376; Ｉｎｔ．Ｊ．Ｃａｎｃｅｒ．，２００４　Ａｕｇ　２０，１１１（２），ｐ．２１３-７ *
JPN6012059377; Ｂｒ．Ｊ．Ｃａｎｃｅｒ．，２００６　Ｊｕｎ　１９，９４（１２），ｐ．１８７９-８６ *
JPN6012059379; Ｊ．Ｃｌｉｎ．Ｏｎｃｏｌ．，２００６　Ａｕｇ　１０，２４（２３），ｐ．３７４７-５５ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500638A (ja) * 2011-11-30 2015-01-08 ジェネンテック， インコーポレイテッド 癌におけるｅｒｂｂ３変異
JP2017531433A (ja) * 2014-10-09 2017-10-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 上皮細胞増殖因子受容体キナーゼドメインにおける変異

Also Published As

Publication number Publication date
EP2094850B1 (en) 2013-06-12
EP2094850A4 (en) 2010-08-04
WO2008066498A1 (en) 2008-06-05
SG177225A1 (en) 2012-01-30
US20110008347A1 (en) 2011-01-13
EP2094850A1 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
JP2010511382A (ja) 癌関連タンパク質キナーゼ
US9364477B2 (en) Mutant ROS expression in human cancer
JP6575950B2 (ja) Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
KR101862719B1 (ko) 단백질 키나제 억제제에 대한 감수성 예측용 바이오 마커 및 이의 용도
US20100081153A1 (en) Cancer associated protein kinases and their uses
US20170107579A1 (en) E1 enzyme mutants and uses thereof
JP2004504009A (ja) 新規ヒト蛋白質キナーゼおよび蛋白質キナーゼ様酵素
WO2013024144A1 (en) Markers for susceptibility to an inhibitor of an src-family kinase
CN101732717A (zh) 用于诊断和作为癌症治疗靶标的ttk
US20140378324A1 (en) Raf dimers and uses thereof
Uchida et al. Stress-activated mitogen-activated protein kinases c-Jun NH2-terminal kinase and p38 target Cdc25B for degradation
US20060141529A1 (en) Compositions, kits and assays containing reagents directed to cortactin and an ARG/ABL protein kinase
CA2697887A1 (en) Modulating and/or detecting activation induced deaminase and methods of use thereof
Shillingford Insights into the Allosteric Regulation and Exploitation of the MAPK Phosphatases as Therapeutic Targets
WO2012075318A2 (en) Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
Montecchini TERAPIA DI PRECISIONE PER LA LEUCEMIA LINFOBLASTICA ACUTA PEDIATRICA BCR-ABL-LIKE: SVILUPPO DI UN SISTEMA IN VITRO PER LA DIAGNOSI E IL MONITORAGGIO CLINICO
US20040048310A1 (en) Novel human protein kinases and protein kinase-like enzymes
Chen et al. Palmitoylation-dependent activation of NADK promotes NADP+ synthesis and tumorigenesis
Mutic Effect of MAPK inhibition on cell cycle regulation of thymidine kinase 1 and [18F]-FLT PET
Lindholm Bachelor of Science
HK1210482B (en) Mutant ros expression in human liver cancer
AU2007237228A1 (en) Cancer associated protein kinases and their uses
HK1165007B (en) Mutant ros expression in human liver cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130311

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130411

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702